Placebo, EP262, -, EP262 clinical trials

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

This study is testing a new medicine, EP262, for people with chronic spontaneous urticaria (CSU), also known as chronic hives. It aims to see if the medicine can reduce itching and the number of hives compared to a dummy medicine.